Strategic partnerships Nabla Bio has established strategic collaborations with major pharma players including AstraZeneca, Bristol Myers Squibb, and Takeda, indicating a proven outbound partner interest model and potential for expanded co-development or licensing discussions with additional pharma ecosystem players.

Generative protein design The company focuses on AI-driven and wet-lab technologies for rational design of developable, selective, and functional drugs, presenting opportunities to position partner-enabled projects around novel target spaces that are currently undruggable, appealing to capacity-starved biopharma pipelines.

Significant funding With a total funding of 37 million and a recent 26 million Series A, Nabla Bio demonstrates strong investor backing and a scalable roadmap, making them a credible partner for milestone-driven collaborations and multi-year research programs.

Pipeline impact potential The company asserts potential to double the number of disease-relevant drug targets advanced by the industry, suggesting high-value collaboration angles in target expansion programs, platform licensing, and integrated drug discovery services.

Location and talent Technical team based in Cambridge, MA with ongoing talent recruitment in ML and synthetic biology, offering a US-based collaboration hub and potential for on-site or nearshore joint development centers to accelerate joint programs.